Mometasone furoate is a glucocorticoid receptor agonist with anti-inflammatory and anti-allergic activity. Mometasone furoate acts as a corticosteroid agent and used for topical applications in chronic skin eczema and airway inflammation management of asthma in vivo. Mometasone furoate exhibits high potency with greater anti-inflammatory activity and a longer duration of action than betamethasone. The molecular biotransformation of mometasone furoate in the skin results in a lower affinity with dermal cells than epidermal cells, which contributes to its low atrophogenicity[3]. Breast cancer patients receiving MF (Mometasone Furoate) during PMRT (postmastectomy radiation) experienced significantly reduced rates of moist desquamation in comparison with a control cream[4].